Rani Therapeutics Holdings ( (RANI) ) has provided an update.
On May 1, 2025, Rani Therapeutics Holdings, Inc. received a compliance deficiency notice from the Nasdaq Stock Exchange due to its Market Value of Listed Securities falling below the required $50,000,000 for 30 consecutive business days. The company has until October 28, 2025, to rectify this issue by maintaining the minimum market value for 10 consecutive days, or face potential delisting. Rani Therapeutics is considering its options to regain compliance, though no decisions have been made yet.
Spark’s Take on RANI Stock
According to Spark, TipRanks’ AI Analyst, RANI is a Underperform.
Rani Therapeutics Holdings’ overall stock score reflects significant financial struggles with no revenue and consistent net losses. The technical analysis shows a bearish trend, and the valuation is challenging with a negative P/E ratio. Strategic advancements in technology and potential partnerships are positive but are overshadowed by financial constraints and high leverage.
To see Spark’s full report on RANI stock, click here.
More about Rani Therapeutics Holdings
Average Trading Volume: 297,583
Technical Sentiment Signal: Sell
Current Market Cap: $62.15M
For detailed information about RANI stock, go to TipRanks’ Stock Analysis page.